Compare VF Corp (VFC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? VF Corp trades at $12.94 (market cap $5.19B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 25.8× VF Corp's market cap, and VF Corp pays a 2.73% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VFC | VRTX | |
|---|---|---|
Market Cap | $5.19B | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $21.55 | $557.96 |
52-Week Low | $12.91 | $376.62 |
Enterprise Value | $9.47B | $128.18B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $13.20, down 1.86% on the day, with a bearish technical outlook and recent earnings misses. The company reported a net loss of $189.72 million for 2025, though revenue of $9.50 billion and a gross margin of 54.97% show underlying strength. Analyst consensus is a Hold with a $17.38 price target, reflecting cautious optimism amid Vans brand challenges.
The stock offers value with a low P/S of 0.55, but execution risks persist. Upside depends on a Vans turnaround and debt reduction, while downside risks include weak consumer sentiment and competitive pressures. Near-term volatility is likely pending Q3 2026 earnings results.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
